Delving into the Latest Updates on Meilaipu (Beijing) Pharmaceutical Research Co., Ltd. with Synapse

Overview

Tags

Otorhinolaryngologic Diseases

Congenital Disorders

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

CSF-1R x FGFRs x FLT3 x PDGFRs x VEGFR	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Nintedanib esylate ( CSF-1R x FGFRs x FLT3 x PDGFRs x VEGFR )	Advanced Lung Non-Small Cell Carcinoma More	Phase 3
Salmeterol xinafoate/Tiotropium Bromide Hydrate ( M3 receptor x β2-adrenergic receptor )	Pulmonary Disease, Chronic Obstructive More	Discontinued